new trials in! ae they part of phase 3 hd? , page-13

JC I don't get much time these days for research either. The claims I was thinking about were for AD, not stroke. Sorry.
Here is the co that owns Etanercept, or Enbrel as it is known.
http://finance.yahoo.com/news/amgen-blazed-biotech-trail-earned-225100069.html
"Nowadays, Amgen is a gray eminence among biotechs. With more than $18 billion in sales last year, it's the kingpin in an industry that's turned into one of America's biggest innovation machines, and one of the highest-returning stock groups of the last few years.

It's hard to believe now, but back in the 1980s biotech was still a largely unproven business model. And Amgen (AMGN), founded in 1980 and public in 1982, was one of the first to show what could be done.

"When I think of the forefathers of biotech, I think of Amgen and Genentech," said Les Funtleyder, author of "Healthcare Investing:"
""The person who leads a good scientific team has to have tremendous respect for science. He has to be able to differentiate good science from bad. And then from there on, it's mostly a support function," Rathmann said at the time. "Get the guy the money, get him the facilities, and get him the resources to make it possible to sustain the effort all the way to the marketplace."
That comment from their first CEO could apply to Prana. They are still on track to be the first disease modifying HD drug.
Regarding stroke. Remember Prof Barnham was given a grant to investigate PBT2 effect on excitotoxicity. There have been no results from that research yet.